| Absorption | Topical use of apraclonidine ophthalmic solution leads to systemic absorption. Studies of apraclonidine (0.5% ophthalmic solution) dosed one drop three times a day in both eyes for 10 days in normal volunteers yielded mean peak and trough concentrations of 0.9 ng/mL and 0.5 ng/mL, respectively. |
| Volume of distribution | Not Available |
| Protein binding | 98.7% |
| Metabolism | |
| Route of elimination | Not Available |
| Half life | 8 hours |
| Clearance | Not Available |
| Toxicity | Accidental or intentional ingestion of oral apraclonidine has been reported to cause apnea, arrhythmias, asthenia, bradycardia, conduction defects, diminished or absent reflexes, dryness of the mouth, hypotension, hypothermia, hypoventilation, irritability, lethargy, miosis, pallor, respiratory depression, sedation or coma, seizure, somnolence, transient hypertension, and vomiting. |
| Affected organisms |
|
Apraclonidine
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment